Table 1.
Baseline demographics of MORE-CRT MPP study patients who were classified as non-responder despite high BIV pacing percentage (whole cohort and MPP and BIV groups)
| Whole cohort subjects (N = 593) |
MPP subjects (N = 291) |
BIV subjects (N = 302) |
P value | |
|---|---|---|---|---|
| Age (years) Mean ± standard deviation (N) | 67 ± 10 (593) | 67 ± 10 (291) | 68 ± 11 (302) | 0.5879 |
| Gender, % (n/N) | ||||
| Female | 22.6% (134/593) | 20.3% (59/291) | 24.8% (75/302) | 0.1844 |
| Male | 77.4% (459/593) | 79.7% (232/291) | 75.2% (227/302) | |
| New York Heart Association Class, % (n/N) | ||||
| II | 50.8% (301/593) | 50.9% (148/291) | 50.7% (153/302) | 0.9760 |
| III | 46.9% (278/593) | 47.1% (137/291) | 46.7% (141/302) | |
| IV | 2.2% (13/593) | 2.1% (6/291) | 2.3% (7/302) | |
| Ischemic cardiomyopathy, % (n/N) | 54.0% (320/593) | 54.0% (157/291) | 54.0% (163/302) | 0.9958 |
| Medical history, % (n/N) | ||||
| Hypertension | 62.7% (372/593) | 63.6% (185/291) | 61.9% (187/302) | 0.6772 |
| Hypercholesterolemia | 43.0% (255/593) | 46.4% (135/291) | 39.7% (120/302) | 0.1017 |
| Myocardial infarction | 37.9% (225/593) | 39.9% (116/157) | 36.1% (109/163) | 0.1698 |
| Diabetes mellitus | 37.6% (223/593) | 37.1% (108/291) | 38.1% (115/302) | 0.8082 |
| Renal disease | 19.6% (116/593) | 20.6% (60/291) | 18.5% (56/302) | 0.5241 |
| Chronic obstructive pulmonary disease | 9.6% (57/593) | 9.6% (28/291) | 9.6% (29/302) | 0.9936 |
| Stroke | 3.9% (23/593) | 4.5% (13/291) | 3.3% (10/302) | 0.4661 |
| TIA | 3.2% (19/593) | 4.1% (12/291) | 2.3% (7/302) | 0.2119 |
| Medication, % (n/N) | ||||
| ACE/ARBs | 87.5% (519/593) | 86.6% (252/291) | 88.4% (267/302) | 0.5043 |
| Beta-blockers | 85.7% (508/593) | 86.3% (251/291) | 85.1% (257/302) | 0.6882 |
| Diuretics | 76.6% (454/593) | 77.3% (225/291) | 75.8% (229/302) | 0.6681 |
| ACE | 61.4% (364/593) | 60.5% (176/291) | 62.3% (188/302) | 0.6580 |
| Statins | 61.0% (362/593) | 62.5% (182/291) | 59.6% (180/302) | 0.4629 |
| Aldosterone antagonist | 37.3% (221/593) | 39.5% (115/291) | 35.1% (106/302) | 0.2658 |
| Antiplatelets | 56.2% (333/593) | 56.0% (163/291) | 56.3% (170/302) | 0.9457 |
| Anticoagulants | 30.9% (183/593) | 30.6% (89/291) | 31.1% (94/302) | 0.8865 |
| ARBs | 29.5% (175/593) | 30.6% (89/291) | 28.5% (86/302) | 0.5738 |
| Anti-arrhythmics | 20.4% (121/593) | 20.3% (59/291) | 20.5% (62/302) | 0.9386 |
| Calcium channel blockers | 7.9% (47/593) | 7.6% (22/291) | 8.3% (25/302) | 0.7463 |
| Nitrates | 7.6% (45/593) | 7.2% (21/291) | 7.9% (24/302) | 0.7370 |
| Ventricular conduction disease, % (n/N) | ||||
| Left bundle branch block | 60.2% (292/485) | 60.7% (145/239) | 59.8% (147/246) | 0.8372 |
| Intra ventricular conduction delay | 26.4% (128/485) | 24.3% (58/239) | 28.5% (70/246) | 0.2955 |
| Right bundle branch block | 10.1% (49/485) | 11.7% (28/239) | 8.5% (21/246) | 0.2455 |
| Left anterior fascicular block | 6.8% (33/485) | 5.9% (14/239) | 7.7% (19/246) | 0.4146 |
| QRS interval Mean ± standard deviation (N) | 156 ± 24 (544) | 156 ± 24 (261) | 156 ± 25 (283) | 0.9016 |
| Left ventricle end systolic volume (ml) Mean ± standard deviation (N) | 155 ± 67 (593) | 155 ± 64 (291) | 156 ± 69 (302) | 0.9002 |
| Left ventricle ejection fraction (%) Mean ± standard deviation (N) | 27 ± 8 (593) | 27 ± 8 (291) | 27 ± 7 (302) | 0.7793 |
ACE, Angiotensin-converting enzyme; ARB, Angiotensin II receptor blocker.